Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | WHR1 | P49842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535668 | 0.93 | CNR2 (0.39) | SCN9ASCN5AWHR1FFAR4SCN10A | |
| SCHEMBL16056964 | 0.90 | SCN9A (0.40) | SCN9ASCN5AFFAR4SCN10A | |
| SCHEMBL17535766 | 0.89 | SCN9A (0.41) | SCN9ASCN5ASCN10A | |
| SCHEMBL16056619 | 0.85 | KDM4E (0.46) | GAA | |
| SCHEMBL17535813 | 0.82 | WHR1 (0.38) | WHR1FFAR4SCN10AGAA | |
| SCHEMBL17535348 | 0.79 | ALDH1A1 (0.51) | WHR1FFAR4GAA | |
| SCHEMBL17535914 | 0.78 | SCN9A (0.39) | SCN9ASCN5AFFAR4SCN10A | |
| SCHEMBL17535506 | 0.78 | GAA (0.40) | SCN9ASCN5AGAA | |
| SCHEMBL17535682 | 0.77 | SCN9A (0.40) | SCN9ASCN5AFFAR4SCN10A | |
| SCHEMBL17535415 | 0.76 | NR1I2 (0.35) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | SCN9A 771/4885SCN5A 111/4885WHR1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.